These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

827 related items for PubMed ID: 16518379

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pegaptanib for wet macular degeneration.
    Fraunfelder FW.
    Drugs Today (Barc); 2005 Nov; 41(11):703-9. PubMed ID: 16395411
    [Abstract] [Full Text] [Related]

  • 3. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.
    Chong V.
    Ophthalmologica; 2012 Nov; 227 Suppl 1():2-10. PubMed ID: 22517120
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.
    Tolentino M.
    Surv Ophthalmol; 2011 Nov; 56(2):95-113. PubMed ID: 21335144
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases.
    Ng EW, Adamis AP.
    Ann N Y Acad Sci; 2006 Oct; 1082():151-71. PubMed ID: 17145936
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration.
    Ng EW, Adamis AP.
    Can J Ophthalmol; 2005 Jun; 40(3):352-68. PubMed ID: 15947805
    [Abstract] [Full Text] [Related]

  • 11. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration.
    Macugen AMD Study GroupDepartment of Ophthalmology and Visual Sciences, Washington University in St. Louis School of Medicine, St. Louis, Missouri 63110, USA., Apte RS, Modi M, Masonson H, Patel M, Whitfield L, Adamis AP.
    Ophthalmology; 2007 Sep; 114(9):1702-12. PubMed ID: 17509689
    [Abstract] [Full Text] [Related]

  • 12. Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy.
    Starita C, Patel M, Katz B, Adamis AP.
    Dev Ophthalmol; 2007 Sep; 39():122-148. PubMed ID: 17245083
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.
    Ciulla TA, Rosenfeld PJ.
    Curr Opin Ophthalmol; 2009 May; 20(3):166-74. PubMed ID: 19381089
    [Abstract] [Full Text] [Related]

  • 16. Pegaptanib for the treatment of age-related macular degeneration.
    Zhou B, Wang B.
    Exp Eye Res; 2006 Sep; 83(3):615-9. PubMed ID: 16678158
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of Topical Instillation of Pegaptanib Sodium Upon Inflammatory Corneal Neovascularization in Rabbits.
    Andrade N, Crispim Ribeiro J, Araújo E Silva PM, Savio D, Fechine FV, de Moraes MO.
    J Ocul Pharmacol Ther; 2021 Jun; 37(5):277-283. PubMed ID: 33891495
    [Abstract] [Full Text] [Related]

  • 19. Simultaneous but not prior inhibition of VEGF165 enhances the efficacy of photodynamic therapy in multiple models of ocular neovascularization.
    Ju M, Mailhos C, Bradley J, Dowie T, Ganley M, Cook G, Calias P, Lange N, Adamis AP, Shima DT, Robinson GS.
    Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):662-70. PubMed ID: 18235012
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.